|
Exclusive Video Q&A With Timothy M. Mayleben, CEO of Aastrom Biosciences
LOS ANGELES, CA, Apr 09, 2012 (MARKETWIRE via COMTEX) --
Last month, Aastrom Biosciences, Inc. (NASDAQ: ASTM) announced that
it had completed an impressive, $40 million private placement
financing. The development was noted as a particularly bullish sign
for emerging biotechs everywhere.
In an exclusive interview, Timothy Mayleben, who has served as
Aastrom's President and CEO since late 2009, explains how the
financing came to be and why investors sought out his firm to place
the big bet on their future.
Aastrom Biosciences is a regenerative medicine company engaged in the
development of autologous cell products for treatment of severe,
chronic cardiovascular diseases. Their proprietary cell-processing
technology enables the manufacture of ixmyelocel-T, a
patient-specific multicellular therapy expanded from a patient's own
bone marrow and delivered directly to damaged tissues. The cellular
therapy resulting from this process contains expanded populations of
mixed stem and progenitor cells to support the regeneration of
cardiovascular tissue. The company's cell manufacturing process works
exclusively with adult stem cells derived from and administered to
the same patient. This approach reduces the risk of rejection and
increases the likelihood of integration with the surrounding tissues,
eliminating the need for immunosuppressive drugs.
Mayleben's exclusive interview with BioMedReports is now available
at:
http://www.biomedreports.com/2012040992513/qaa-timothy-mayleben-ceo-of-aastrom-biosciences.html
Healthcare investors and Biotech traders interested in accessing
BioMedReports' new complete database of clinical trials and upcoming
FDA and world-wide regulatory decisions which can be used to make
more profitable trades and see upcoming catalysts can go to:
http://biomedreports.com/fdacal.html
News developments and live healthcare sector updates are available
constantly via Twitter at: http://twitter.com/BioMedReports
About BioMedReports.Com
BioMedReports is a news and research portal covering financial
biomedical news and the entire Healthcare Sector of the market.
BioMedReports is not paid or compensated to report the news and
developments of publicly traded companies. They sell a premium
product for subscribers and full disclosures and information about
the stocks and news mentioned in this news release is available at
BioMedReports.Com
Media Contacts Only:
Mary Davila
Assistant Editor
BioMedReports.Com
e-mail: Email Contact
Tel: +1 323 472 4480
Fax: +1 888 210 3556
SOURCE: BioMedReports
http://www2.marketwire.com/mw/emailprcntct?id=AD629A7865DC6068
[ Back To SIP Trunking Home's Homepage ]
|
NEW Bring Your Own Device
(BYOD): HTML5 and Google's WebRTC are
transforming our industry: The disaggregation of the telecom industry has long
been talked about, while available solutions remain
vertically integrated in spite of a growing industry of
standards-based individual components...
NEW SSOA - SIP Service Oriented Architecture™:
Cloud and large enterprise communications
and collaboration infrastructure: This eBook introduces eZuce's SIP Service Oriented
Architecture (SSOA). SSOA is a 'carrier-class'
system that offers the demanding global enterprise
a modern built-for-the-cloud and highly
scalable...
NEW Benefits of Broadvox VAR Partner Program: We built our Partner Program to work for you. We understand that different
types of partners have different needs, and we don't play favorites. When
you partner with Broadvox, every member of our team stands behind you
and your customers 100%... 
What's New?
